Key Takeaways
- Margin hit on inventory lag, recovery promised: EBITDA margin fell to 17% in Q3 as high-cost inventory met lower CPVC realizations, but management expects an uptick from Q4 as PVC prices have bottomed and started rising.
- Volume momentum turned mid-quarter: Revenue grew just 2% QoQ after a first half weighed down by prolonged monsoon, festive disruptions and plant maintenance; volumes picked up strongly from mid-November and that momentum is expected to persist.
- Chlorotoluene nearing revenue inflection: Customer approvals are converting to full-truckload deliveries, and management expects sizable P&L contribution from Q1 FY27, with long-term contracts forming from that point.
- ECH pricing finds a floor: European competitors are permanently shutting capacity amid tight conditions, while glycerin costs stay elevated on biodiesel policy; management calls current ECH pricing "a new normal which will continue."
- What to watch next quarter: Whether CPVC margins actually rebound as guided, the pace of chlorotoluene contract formation, and any announcement of new chemistry capex plans expected by fiscal year-end.
CPVC: The Margin Reset
- The Q3 squeeze: CPVC realizations fell in line with PVC prices, which dropped substantially over the prior 4-5 months, while inventory carried at higher cost from the monsoon period of low offtake. That mismatch compressed margins in the quarter.
- The recovery case: PVC prices have bottomed and started moving up; CPVC prices follow with a lag of about 1 to 1.5 months. Management expects Q4 margins to improve as lower-cost inventory works through and realizations catch up.
- Demand absorption: Industry CPVC demand is estimated around 280,000 tonnes, and management believes new domestic supply will eventually be absorbed by growing demand, though it declined to share a precise internal forecast.
- Competitive landscape: Reliance is commissioning a small CPVC capacity (~11 Kt) this year; Adani has not yet announced. When asked whether pipe companies like Supreme or Prince might backward-integrate as Astral has, management said it is "difficult to comment," noting the B2B CPVC business requires a different mindset than B2C pipes.
Kotecha: "Q3 was impacted because of the high cost of inventory and also the realizations for the product has cooled off. So considering that, we believe that Q3 was impacted in that manner. But Q4 onwards, we believe that the margin will be uptick."
Chlorotoluene Value Chain: The Next Growth Leg
- Where it stands: The plant commissioned in March 2025 and volumes are increasing month-on-month and quarter-on-quarter. Multiple products have received end-user approvals and are shipping on a full-truckload basis, not samples.
- The ramp cadence: Customers change supply sources gradually; confidence builds over time. Management expects major orders and long-term contracts to start forming from Q1 FY27, with sizable P&L contribution from that point. Current business is on a quarterly basis.
- Infrastructure investment: A pilot plant is being built on campus to support downstream development, quality improvement and sampling for chlorotoluene derivatives, future products and CPVC compounding. This is for internal testing, not pipe manufacturing.
- Numbers withheld: Management declined to share utilization percentages or revenue expectations for FY27, saying volumes have not yet reached a sizable level and it is too early to commit to numbers.
ECH & Caustic Soda: Structural Shifts
- ECH pricing support: Glycerin prices are elevated because the US is not supporting biodiesel, and glycerin is a biodiesel byproduct. Since 65% of global ECH demand is now glycerin-based, that cost floor holds. European manufacturers are permanently closing plants because the current environment is very tight.
- The new normal: Management believes current ECH pricing is sustainable and will continue. If glycerin prices rise further, ECH prices will follow with a lag of roughly one quarter.
- No forward integration planned: Despite the tight environment, management sees enough standalone ECH demand going forward and has no plans to integrate downstream.
- Caustic soda dynamics: Large domestic capacities being built by Adani and Reliance include forward integration into PVC, meaning chlorine will be fully consumed in-house while caustic becomes excess. Management expects caustic prices to fall and chlorine prices to rise once those plants commission.
Patel: "The Trump is not supporting the biodiesel project and the glycerin is a byproduct of biodiesel, so the glycerin price is going to remain high till the biodiesel are not getting supported by the global leaders."
Capex Pipeline & Capacity Expansion
- On-track projects: Capacity doubling at CPVC, epichlorohydrin and wind-solar hybrid power plants are progressing on schedule and within budget, with commissioning expected by the announced timeline.
- Post-commissioning ramp: When the CPVC and ECH plants commission (expected September 2026), management anticipates running at lower utilization for an initial 6 months to a year due to teething problems, but expects to reach optimum levels within 1-2 years given demand growth.
- Next wave of projects: The company is finalizing capex plans for new projects and expects to announce details in the coming months, with these initiatives set to drive significant growth from FY29 onwards. A new chemistry announcement is in advanced stages and expected by the end of this financial year.
- Strategic target: The company is targeting 70% revenue contribution from derivatives and specialty business.
Kotecha: "Maybe for initial 6 months or a year's time, we have to run our plant at lower utilizations. But eventually... we tend to believe that in maybe a matter of 1 or 2 years, we should be able to run our plant at optimum utilization levels even after considering the new capacities which are coming because growth in India is there."
Demand Environment & Pricing
- What hurt H1: The first half of FY26 was muted by early and prolonged monsoon, subdued demand and festive-season disruptions. Exports remained weak, and US-India trade progress stalled.
- The turn: Volumes picked up strongly from mid-November onwards, and management expects that positive momentum to persist. Demand has picked up, and coming quarters will be much better than the last 6-9 months.
- Global price tailwind: China has withdrawn export rebates on 250 products, and commodity and petrochemical prices globally have started moving up from this quarter. Management sees this as a broad-based recovery signal.
- Budget clarity ahead: The company's budgeting exercise starts this month, with more clarity on next year expected by March.
Patel: "China has announced 250 products, they have withdrawn the rebate of the product. So I think globally and other petrochemical products are also going up. So all commodity prices are going up."
Financials in Brief
- Revenue: Grew 2% QoQ; 9-month revenue at INR 1,807 crores, down 7% YoY.
- EBITDA margin: 17% in Q3 vs 22% over 9 months FY26 vs 28% in the corresponding 9-month period, with the dip driven by lower realizations and higher raw material costs.
- PAT: INR 39 crores, down from INR 51 crores in the prior quarter, including a small one-time expense for a Labor Code change already booked in the income statement.
- Utilization: 76% over 9 months vs 82% in the corresponding period. Management declined to provide product-level utilization splits.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CPVC margin recovery | Margins to uptick from Q4 as lower-cost inventory replaces high-cost stock and realizations improve | Q4 FY26 onwards |
| Chlorotoluene revenue contribution | Sizable P&L contribution; long-term contracts to form | Q1 FY27 onwards |
| CPVC/ECH capacity commissioning | Doubling projects on track within announced timeline and budget | Expected September 2026 |
| Post-expansion utilization ramp | Run at lower utilization for initial 6-12 months, reach optimum in 1-2 years | FY27-FY29 |
| New capex/chemistry announcement | Details of new projects and new chemistry to be disclosed | By end of FY26 / coming months |
| Next-wave project contribution | New initiatives to drive significant growth | FY29 onwards |
| Volume growth | Good volume growth expected | FY27 |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue | ₹603 cr, +2% QoQ |
| EBITDA | ₹103 cr, -22% QoQ |
| EBITDA margin | 17%, contracted from prior quarter; 9-month FY26 margin at 22% |
| PAT | ₹39 cr, vs ₹51 cr in prior quarter; includes one-time labor code expense |
| 9-month FY26 revenue | ₹1,807 cr, -7% YoY |
| 9-month FY26 EBITDA | ₹398 cr, margin at 22% vs 28% in corresponding period |
| Derivatives & specialty revenue share | 52%, up from 50% QoQ |
| Overall plant utilization | 78%, flat QoQ; 81% in Q3 FY25 |
| 9-month FY26 plant utilization | 76%, vs 82% in corresponding period |
| ROCE | 17% as on 31 Dec 2025; 20% excluding capital work in progress |
| Net debt | ₹557 cr, vs ₹531 cr as on 31 Dec 2024 |
| Net debt to EBITDA | 1x, vs 0.8x as on 31 Dec 2024 |
| Capex spent during FY26 | ₹337 cr |
| ECU | ₹29,000–30,000, marginally down ₹500–1,000 QoQ |
| CPVC realization | ₹95–100 per kg |
| ECH realization | ₹165–170 per kg |
| Chlorine integration | 70–75% |
| CPVC demand (India) | ~280,000 tonnes expected by 31 Mar 2026, growing 10–12% annually |